Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARB impact on camrelizumab plus chemotherapy in first-line advanced non-small cell lung cancer
ChiCTR2500097155Phase 4Not yet recruiting
- Sponsor
- Wuxi People's Hospital
- Start
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Wuxi People's Hospital. Primary endpoint: Objective response rate. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500097155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097155.